Spotlight on teriflunomide.

Abstract

Currently, licensed disease-modifying agents for multiple sclerosis (MS) all share the need for parenteral administration. Oral therapies would carry the advantage of convenience and greater acceptability. Teriflunomide is one of several oral agents currently undergoing Phase III investigation. This article describes the mode of action of teriflunomide which largely depends on inhibition of pyrimidine synthesis. We review the evidence so far on the efficacy of teriflunomide in animal models and Phase II human studies. In view of teriflunomides favourable safety profile it appears to be a promising oral alternative to interferon beta and glatiramer acetate. The ongoing Phase III investigations of teriflunomide as mono- and combination therapy are discussed.

0204060200920102011201220132014201520162017
Citations per Year

89 Citations

Semantic Scholar estimates that this publication has 89 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Tallantyre2008SpotlightOT, title={Spotlight on teriflunomide.}, author={Emma C Tallantyre and N. Evangelou and Cris S. Constantinescu}, journal={International MS journal}, year={2008}, volume={15 2}, pages={62-8} }